Literature DB >> 24281125

Complete response of primary bladder adenocarcinoma with the FOLFOX4 regimen.

A M Tatli1, M Uysal, S S Goksu, S Gunduz, D Arslan, M Ozdogan.   

Abstract

INTRODUCTION: Primary adenocarcinoma of the bladder is a very rare disease that is difficult to treat. In this paper, we report the second case in the literature with primary mucinous adenocarcinoma of the bladder which showed complete response to FOLFOX4 (fluorouracil, leucovorin, oxaliplatin) chemotherapy regimen. CASE REPORT: A 41-year-old man was admitted to our hospital with a diagnosis of primary adenocarcinoma of the bladder. Due to the similarity in histology with colon carcinoma, a FOLFOX4 regimen was started. Complete response was achieved at the end of this treatment. Today the patient is free of local or systemic disease.
CONCLUSION: FOLFOX4 regimen may be a treatment option for primary adenocarcinoma of the bladder. 2013 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24281125     DOI: 10.1159/000354332

Source DB:  PubMed          Journal:  Urol Int        ISSN: 0042-1138            Impact factor:   2.089


  3 in total

1.  U-shaped relationship of age at diagnosis and cancer-specific mortality in primary urachal adenocarcinoma: a cohort study.

Authors:  Dong-Dong Yu; Hui Dong; Zhi-Gang Wu; Yun-Bei Xiao; Chao-Feng Zhou; Qin-Quan Wang; Jian Cai
Journal:  Transl Androl Urol       Date:  2020-06

2.  Advanced primary nonurachal adenocarcinoma of urinary bladder responding to modified FOLFOX6 and capecitabine: a case report.

Authors:  Frank S Fan; Chung-Fan Yang
Journal:  Oxf Med Case Reports       Date:  2018-08-11

3.  Development and validation of a nomogram for predicting survival in patients with non-metastatic primary adenocarcinoma of the bladder.

Authors:  Dong-Dong Yu; Hui Dong; Wei-Kang Chen; Kun Chen; Zhi-Gang Wu; Cheng-Di Li; Jian Cai; Yun-Bei Xiao
Journal:  Transl Cancer Res       Date:  2020-09       Impact factor: 1.241

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.